For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients¹

Abbvie's commitment to
exceptional
access and patient support

Get started with the
Enrollment & Prescription Form

Download the RINVOQ Complete Enrollment & Prescription Form

Explore commercial coverage in your area

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

RINVOQ is for moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients¹

EXCEPTIONAL COMMERCIAL COVERAGE
FOR RINVOQ (upadacitinib) in RA

RINVOQ has >95% preferred commercial coverage - National commercial formulary coverage under the pharmacy benefit as of September 2023

Payers cover RINVOQ after the trial of 1 TNFi with >95% preferred coverage

Commercial plan preferred formulary status for TIM therapies for moderate to severe RA under the pharmacy benefit as of September 2023^2,‡

National commercial plan formulary status under the pharmacy benefit

Preferred coverage also could mean a STANDARD PRIOR AUTHORIZATION (PA) and APPEALS PROCESS, potential for one-time PA/appeal approval.

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^‡Percentages reflect anticipated coverage.

JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Preferred coverage also could mean a
STANDARD PRIOR AUTHORIZATION (PA)
and APPEALS PROCESS, potential for one-time PA/appeal approval.

Cimzia, Actemra, and Orencia are available as products on medical benefits plans.

Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.

Products listed here are not interchangeable with one another. Not all products are shown, including biosimilars. Material differences exist between the listed products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.

No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^‡Percentages reflect anticipated coverage.

JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Please see HUMIRA full Prescribing Information.

Look up commercial insurance plans for RINVOQ in your area

Select a filter

Plan Name
Plan Type

EXCEPTIONAL MEDICARE
PART D COVERAGE FOR RINVOQ (upadacitinib) in RA

Medicare Part D preferred coverage - RINVOQ has achieved >95% Preferred Medicare Part D coverage - Medicare Part D formulary coverage under the pharmacy benefit as of September 2023

Medicare Part D plan preferred formulary status for TIM therapies for moderate to severe RA under the pharmacy benefit as of September 2023^2,‡

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^‡Percentages reflect anticipated coverage.

JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Cimzia, Actemra, and Orencia are available as products on medical benefits plans.

Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.

No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^‡Percentages reflect anticipated coverage.

JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Please see HUMIRA full Prescribing Information.

Two products.
One exceptional patient experience.

NURSE
AMBASSADORS^*

Empower patients

Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete

Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:

Help patients understand the importance of following the treatment plan prescribed by their healthcare professional.
Committed to answering questions throughout the experience to help limit treatment disruptions.
Answer patients’ insurance questions and connect them with additional insurance expertise.
Identify ways for patients to save on prescription costs.

ACCESS
SPECIALISTS

Insurance support when needed

Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.

ACCESS & SAVINGS

Help with access &
treatment affordability

Complete can help your commercial patients save:

With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.^†
Complete may help eligible commercially insured RINVOQ patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.^‡

Please see HUMIRA full Prescribing Information.

Have questions or need support over the phone?

Call 1-877-COMPLETE (1‑800‑274‑6867)

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment‑related questions, including further referrals.

^†Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib), or HUMIRA® (adalimumab) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com for RINVOQ® patients, and HUMIRASavingsCard.com for HUMIRA® patients, or call 1.8‍0‍0.2‍RINVOQ or 1.8‍0‍0.4‍HUMIRA for additional information To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie

^‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

How to enroll patients in
RINVOQ complete

Help patients get the support they need to start and stay
on track with their prescribed treatment

To enroll a patient in RINVOQ Complete:

Pull your patient’s patient demographic sheet from your Electronic Health Record

Ensure the following information is included: full home address, email address, medical and prescription insurance information, and any relevant clinical details.
Redact the patient’s entire Social Security Number (if present).
Failure to include the patient demographic sheet may result in delayed enrollment.

Download the enrollment & prescription form for your specialty

Fill out the form with your patient

This form enrolls your patient and can be used to initiate a prescription with your patient's preferred specialty pharmacy.
The RINVOQ Complete Prescription section may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

Fax the enrollment & prescription form and the patient demographic sheet to 1-678-727-0690

You will receive a call from an Access Specialist to discuss next steps.
If using the Pharmacy Prescription section, fax a copy to your patient's specialty pharmacy as well.

Inform your patient that they have been enrolled

Let your patient know to expect a call from their Ambassador.

Get started with the enrollment & prescription form

RINVOQ Complete Enrollment & Prescription Form

^*Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

COMPLETE APP

Track treatment

The Complete App helps patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:

Access additional resources, including a savings card for those that are eligible
Set customized medication reminders
Log and share symptoms with HCPs
Log medication lot number and medication expiration date

COMPLETEPRO.COM

Streamline the Rx process

CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.

With CompletePro.com, you can:

Request benefits verifications
Complete and submit prior authorizations
Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
Receive alerts for annual reauthorizations and renewals
Track and monitor where patients are in the prescription process